Skip to main content
SpringerLink
Log in

Potenzieller Kombinationspartner für Chemo- und Radiotherapie

TH-302 — ein neues unter Hypoxie aktiviertes Zytostatikum beim Pankreaskarzinom

  • journal club
  • Published:
Info Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Conroy T et al. for the Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. N Engl J Med. 2011;364(19):1817–25.

    Article  CAS  PubMed  Google Scholar 

  2. Overgaard J Radiother Oncol. 2011;100(1):22–32.

    Article  PubMed  Google Scholar 

  3. Overgaard J. Oncol Res. 1994;6(10-11):509–18.

    CAS  PubMed  Google Scholar 

  4. Bentzen J et al. Acta Oncol. 2015;54(7):1001–7.

    Article  CAS  PubMed  Google Scholar 

  5. Overgaard J et al. Radiother Oncol. 1998;46(2):135–46.

    Article  CAS  PubMed  Google Scholar 

  6. Kuhnt T et al. J Cancer Res Clin Oncol. 2005;131(11):758–64.

    Article  CAS  PubMed  Google Scholar 

  7. Evofosfamide. http://en.wikipedia.org/wiki/Evofosfamide. Zugegriffen: 22. Apr. 2015.

Literatur

  • Erstpubliziert in Strahlenther Onkol. 2015;191(10):819–20.

Originalie

  • Borad MJ et al. Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2015; 33(13):1475–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland

    Claudia Schmalz &  Jürgen Dunst

Authors
  1. Claudia Schmalz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jürgen Dunst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudia Schmalz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schmalz, C., Dunst, J. TH-302 — ein neues unter Hypoxie aktiviertes Zytostatikum beim Pankreaskarzinom. Info Onkol. 19, 25–26 (2016). https://doi.org/10.1007/s15004-016-5297-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-016-5297-9

Schlüsselwörter

Search

Navigation